Neurocrine Biosciences | NBIX - ايرادات المبيعات





مبيعات تغيير تاريخ
AbbVie USD 17.4B 410M 2026-09
Acadia Pharmaceuticals USD 342M 34.04M 2026-09
Agios Pharmaceuticals USD 55.38M 10.64M 2026-09
ALKERMES USD 480.13M 15.88M 2026-09
Alnylam Pharmaceuticals USD 1.46B 170M 2026-09
Amgen USD 10.4B 300M 2026-09
Biogen USD 2.8B 60M 2026-09
BioMarin Pharmaceutical USD 1.03B 40M 2026-09
Cytokinetics USD 47.6M 19M 2026-09
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
Exelixis USD 658.69M 30M 2026-09
Gilead Sciences USD 8.3B 500M 2026-09
Halozyme Therapeutics USD 492.97M 11.97M 2026-09
Incyte USD 1.56B 110M 2026-09
Ionis Pharmaceuticals USD 243M 25M 2026-09
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Neurocrine Biosciences USD 1.12B 161M 2026-09
Pfizer USD 16.6B 1.57B 2026-09
Prothena USD 1.01M 50.07M 2026-06
Regeneron Pharmaceuticals USD 5.12B 830M 2026-09
Repligen USD 209M 5M 2026-09
Rigel Pharmaceuticals USD 55.31M 18.47M 2024-09
Sarepta Therapeutics USD 381.4M 19.9M 2026-09
Teva Pharmaceutical Industries USD 4.37B 8.3B 2026-09
Ultragenyx Pharmaceutical USD 173M 41M 2026-09
Vertex Pharmaceuticals USD 3.44B 110M 2026-09